Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests

v3.21.2
Non-Controlling Interests
6 Months Ended
Jun. 30, 2021
Non-Controlling Interests  
Non-Controlling Interests

13. Non-Controlling Interests

Non-controlling interests in consolidated entities are as follows:

    

    

For the Six Months Ended

    

    

    

    

 

As of June 30, 2021

June 30, 2021

As of June 30, 2021

 

Net loss attributable to

Non-controlling interests

Non-controlling

 

($ in thousands)

    

NCI equity share

non-controlling interests

in consolidated entities

ownership

 

FBIO Acquisition Corp VIII

$

(202)

 

(96)

$

(298)

 

32.0

%

Aevitas

(4,022)

 

(567)

 

(4,589)

 

46.6

%

Avenue 2

 

2,004

 

(1,507)

 

497

 

77.4

%

Baergic

 

(1,916)

 

(20)

 

(1,936)

 

39.5

%

Cellvation

 

(1,356)

 

(70)

 

(1,426)

 

22.1

%

Checkpoint 1

 

57,779

 

(11,643)

 

46,136

 

81.1

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

(1,157)

 

(638)

 

(1,795)

 

29.8

%

Helocyte

 

(5,305)

 

(47)

 

(5,352)

 

18.3

%

JMC

 

800

 

(1,182)

 

(382)

 

7.2

%

Mustang 2

 

133,046

 

(22,066)

 

110,980

 

82.2

%

Oncogenuity

(540)

 

(264)

 

(804)

 

24.9

%

Tamid

 

(721)

 

 

(721)

 

22.8

%

Total

$

178,120

$

(38,100)

$

140,020

 

  

    

For the twelve months ended

    

    

 

As of December 31, 2020

December 31, 2020

As of December 31, 2020

 

Net loss attributable to 

Non-controlling interests 

Non-controlling 

 

($ in thousands)

    

NCI equity share

    

non-controlling interests

    

 in consolidated entities

    

 ownership

 

FBIO Acquisition Corp VIII

$

(7)

(27)

$

(34)

 

10.0

%

Aevitas

(2,370)

(823)

 

(3,193)

 

39.0

%

Avenue 2

 

5,800

(3,974)

 

1,826

 

77.4

%

Baergic

 

(1,662)

(97)

 

(1,759)

 

39.5

%

Cellvation

 

(1,089)

(182)

 

(1,271)

 

22.1

%

Checkpoint 1

 

41,704

(13,265)

 

28,439

 

80.4

%

Coronado SO

 

(290)

 

(290)

 

13.0

%

Cyprium

 

567

(1,478)

 

(911)

 

30.5

%

Helocyte

 

(4,986)

(259)

 

(5,245)

 

18.8

%

JMC

 

138

491

 

629

 

7.1

%

Mustang 2

 

116,060

(36,429)

 

79,631

 

80.9

%

Oncogenuity

(82)

(376)

 

(458)

 

25.3

%

Tamid

 

(663)

(40)

 

(703)

 

22.8

%

Total

$

153,120

$

(56,459)

$

96,661

 

Note 1:

Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2:

Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.